Skip to main content

Home/ Pharmaceutical Laboratory/ Group items tagged improvement

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
hamelinclara

Startup Incubator, Health Wildcatters Unveils First Class of Startups - 0 views

www.hitconsultant.net/...nveils-first-class-of-startups

startup incubator apps

shared by hamelinclara on 26 Aug 13 - No Cached
  • hamelinclara on 26 Aug 13
     
    "Here is a brief introduction Health Wildcatters inaugural class of 12 startups: 20over8 develops a vision testing system that goes beyond the standard eye chart to reflect realistic, real-world testing conditions. Care Starter is an app that gives patients access to information and resources to help them manage their life with a chronic medical condition. Cariloop hosts a digital platform to access real time information about geriatric care and service providers. Fraud ID Standard Technology is a patent pending system of preventing healthcare fraud through a real-time database system. KinesioKinect enables the mainstream use of mobile technologies and motion sensors to lower healthcare costs while improving patient outcomes. MakeMyPlate is a smart engine that guides the decision making process for daily food intake by making the process visual, fun, and easy. MyCounsel delivers mental healthcare providers and consumers greater access to data-based care, while improving many broader societal issues. NeuroTek develops a non-invasive, electronic neuromodulation devices for the treatment of migraines and other diseases. PT PAL's app stores, schedules and tracks personal physical therapy exercises in a way that is intuitive and convenient while also tracking compliance. Remind Technologies develops patient-centric medication adherence technologies that allow patients to be in charge of their own health. Socrates Health Solutions has invented a non-invasive blood glucose monitoring system. SPAtaneity is a professional nail salon experience for those living with diabetes, cancer, and other immune-suppressed conditions"
hamelinclara

Nurep Blog - 0 views

blog.nurep.com/...prove-the-medical-device-sales

medical_device improvement

shared by hamelinclara on 22 Apr 13 - No Cached
  • Scheduling cases can be challenging as cases may occur earlier/later than planned. Trauma cases are rarely ever planned. “The entire OR staff is ready to go and we are waiting for the rep to arrive.”
  •  Physicians abandon complicated devices that fail to offer guaranteed support. “We stopped using the device. We are tired of needing an in-person rep for every question or issue that arises.
  • ) Physicians that have to switch a device in the OR can’t obtain the support they need. “I’d consider switching my business to a device that offers guaranteed real-time support.”
  • ...1 more annotation...
  • 5) Phone support takes too long and is insufficient, as the rep cannot see the issue. “Visuals would have solved the issue in secs; on the phone for 30min w/ patient in shock. We wasted two $35K devices” Potential Result: Delay in care.
hamelinclara

Telemedicine Deemed Critical for Rural Pediatric Care | mHealthWatch - 0 views

mhealthwatch.com/for-rural-pediatric-care-21367

mhealth pédiatrie

shared by hamelinclara on 11 Aug 13 - No Cached
  • hamelinclara on 11 Aug 13
     
    ""The bottom line is that this readily available technology can and should be used to improve the quality of care delivered to critically ill children when there are no pediatric specialists available in their own communities," said James Marcin, director of the UC Davis Children's Hospital Pediatric Telemedicine Program and the study's senior author. "People say a picture is worth a thousand words," said Marcin, professor in the Department of Pediatrics, "With medicine, video conferencing brings us right to the bedside, allowing us to see what's happening and collaborate with on-site doctors to provide the best possible care to our patients.""
hamelinclara

Pharmaceuticals: Companies will focus on external partnerships to improve productivity ... - 0 views

cen.acs.org/...cus-external-partnerships.html

phara 2012 2013

shared by hamelinclara on 20 Jan 13 - No Cached
  • If the buzzword for the pharmaceutical industry in 2012 was “patent cliff,” the key theme for 2013 is “partnership.”
  • maller R&D organizations and budgets, drug companies are putting more emphasis on working relationships with biotech firms or with academia
  • collaboration
  • ...4 more annotations...
  • pharmaceutical leader for the consulting firm Ernst & Young.
  • Patrick Flochel
  • While trying to make their own research efforts more productive, companies are filling gaps in their drug pipelines through acquisitions.
  • n exception may be AstraZeneca, which lost its patent for the antipsychotic drug Seroquel and was hit hard by generics competition. “AstraZeneca is in a pretty dire situation,” Latwis says.
hamelinclara

The search for blockbuster drugs - McKinsey Quarterly - Health Care - Pharmaceuticals - 1 views

www.mckinseyquarterly.com/rch_for_blockbuster_drugs_1474

blockbuster drugs Pharma

shared by hamelinclara on 09 Jan 13 - No Cached
  • "me-too" compounds,
  • heir efficacy, or comparative effectiveness in treating a specific disease
  • safety, including issues such as side effects and drug interactions
  • ...10 more annotations...
  • the breadth of their approved uses
  • convenience, including longer-lasting formulas and easier application
  • highly effective,
  • costly and inconclusive.
  • By contrast, many companies have had more success with efforts to improve the safety of products or to get them approved for use in treating additional diseases. Examples are Pfizer's Neurontin, a successful antiepilepsy medication driven predominantly by perceptions of safety differences, and the company's Celebrex, a Cox-2 inhibitor that reduces pain and inflammation and is thought to be easier on the stomach than aspirin. The breadth of approved uses for drugs can also be a significant source of differentiation. We found that nearly two-thirds of those in competitive therapeutic areas, such as depression and allergies, went on to receive regulatory approval for a broader range of treatments after they came on the market (Exhibit 2). Eli Lilly's Prozac, for example, was launched in 1987 to treat depression but has since been approved for use in a range of conditions. Today, drugs entering these competitive areas often need to have a similarly broad range of regulatory endorsements at the time of their launch, thereby raising the bar for compounds in development
  • pharmaceutical companies might rethink their strategies for clinical trials
  • oo many companies commit a disproportionate amount of their time and money to discovering first-in-class compounds when best-in-class opportunities might yield higher returns
  • Second, efficacy shouldn't be pursued at the expense of other sources of differentiation; claims of safety, pharmacokinetics (that is, dosing), and convenience may be as desirable and more clinically attainable
  • one meaningful point of differentiation and scuttle drugs that have even a single subpar attribute.

  • Of the recent blockbusters we analyzed, 59 percent were superior to the competition in only one area, while just 14 percent were superior in two, and no drug was the leader in three or more (Exhibit 3). While some of the remaining 27 percent were distinctive at launch, they are now comparable to their competitors in all significant dimensions but continue to be marketed more effectively. Yet drugs with even a single subpar attribute were generally commercial failures.1

    Back to top

    These

hamelinclara

How Pharma Companies Use Social Media | Business 2 Community - 1 views

www.business2community.com/...anies-use-social-media-0370041

pharma social_media

shared by hamelinclara on 10 Jan 13 - No Cached
  • branded (sponsored and monitored by a specific brand), non-branded (usually support groups, fundraisers or information-based platforms like WebMD), and healthcare professional communities
  • acebook, Twitter and YouTube, as well as blogs (sponsored and non-sponsored)
  • a lot of opportunity for more engagement and creating educational communities onlin
  • ...2 more annotations...
  • Mayo Clinic did with live tweet chats.
  • to improve business efficiency
hamelinclara

2012 in reflection : Article : Nature Reviews Drug Discovery - 1 views

www.nature.com/...nrd3927.html

Patent

shared by hamelinclara on 09 Jan 13 - No Cached
  • Last year saw the largest loss of revenue yet from major drugs due to patent expiries, but a continuation of 2011's higher level of drug approvals and new initiatives to address R&D challenges provide hope for the future.
  • In September 2012, the non-profit TransCelerate BioPharma was established by Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi, initially to focus on improving clinical trial processes.
  • Incentives to develop breakthrough products were one of the major themes in the fifth incarnation of the US Prescription Drug User Fee Act (PDUFA), authorized in July 2012, through which industry pays fees to the FDA for product review (Nature Rev. Drug Discov. 11, 586–588; 2012).
hamelinclara

Ten Pharmaceutical Companies Unite to Accelerate Development of New Medicines -- PHILAD... - 1 views

www.prnewswire.com/...f-new-medicines-170329346.html

Pharma Research TransCelerate

shared by hamelinclara on 09 Jan 13 - No Cached
  • Ten leading biopharmaceutical companies announced today that they have formed a non-profit organization to accelerate the development of new medicines. Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group, and Sanofi launched TransCelerate BioPharma Inc. ("TransCelerate"), the largest ever initiative of its kind, to identify and solve common drug development challenges with the end goals of improving the quality of clinical studies and bringing new medicines to patients faster.
  • financial and other resources, including personnel, to solve industry-wide challenges in a collaborative environment.
  • among the heads of R&D at major pharmaceutical companies that there is a critical need to substantially increase the number of innovative new medicines,
  • ...2 more annotations...
  • As shared solutions in clinical research and other areas are developed, TransCelerate will involve industry alliances including Clinical Data Interchange Standards Consortium (CDISC), Critical-Path Institute (C-Path), Clinical Trials Transformation Initiative (CTTI), Innovative Medicines Initiative (IMI), regulatory bodies including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), and Contract Research Organizations (CROs).
  • "We applaud the companies in TransCelerate BioPharma for joining forces to address a series of longstanding challenges in new drug development. This collaborative approach in the pre-competitive arena, utilizing the collective experience and resources of 10 leading drug companies and others to follow, has the promise to lead to new paradigms and cost savings in drug development, all of which would strengthen the industry and its ability to develop innovative and much-needed therapies for patients.
hamelinclara

IHE.net Home - 0 views

www.ihe.net/

healthcare standards législation ihe esanté

shared by hamelinclara on 16 Apr 13 - Cached
  • IHE is an initiative by healthcare professionals and industry to improve the way computer systems in healthcare share information. IHE promotes the coordinated use of established standards such as DICOM and HL7 to address specific clinical need in support of optimal patient care. Systems developed in accordance with IHE communicate with one another better, are easier to implement, and enable care providers to use information more effectively.
hamelinclara

Is this the future of hospitals in Canada? - Health - CBC News - 0 views

www.cbc.ca/...pitals-digital-humber-rmh.html

hopital canada oslo ehealth

shared by hamelinclara on 20 Apr 13 - No Cached
  • What's more, "e-health" has become synonymous with government boondoggles. The country has spent $4 billion on the endeavour, but e-health initiatives in Ontario, B.C., N.B. and P.E.I. have all been accused of mishandling the awarding of contracts and having little to show for the amount of money invested.
  • Electronic medical records and other digital technologies have the potential to improve patient outcomes by helping hospitals identify and track infections, medication errors and other adverse events and alerting physicians to drug interactions and other problems.
  • "Most hospitals have implemented technology not to address these issues but to try to either create efficiencies or get better at billing, get better at coding," he said.
  • ...3 more annotations...
  • Technology is just a tool,
  • The Oslo hospital's move to the digital age has also had another bonus: more efficient clinical operations enabled them to reduce the number of days patients spend in the hospital from about 5 to 3.5, Borthne said. (Although technology wasn't much help in 2011, when an increase in patient volume and staffing shortages led to several fatal lapses in patient care.)
  • "One of the lessons we have learned is that a digital system is always error prone, so you can't be sure of having 100 per cent up time for any digital system," Borthne said
hamelinclara

Johnson And Johnson, Novartis, And AbbVie; Three Pharma Stocks That Could Be Good For Y... - 1 views

www.forbes.com/...cks-that-could-be-good-for-you

stocks pharma

shared by hamelinclara on 22 Jan 13 - No Cached
  • hat’s based on less patent exposure, improving pipelines, growing contributions from emerging markets, and cost cutting.
1 - 13 of 13
Showing 20▼ items per page